Visual Telerehabilitation in AMD Patients

Sponsor
Michael Reber (Other)
Overall Status
Recruiting
CT.gov ID
NCT04685824
Collaborator
(none)
32
1
2
16.6
1.9

Study Details

Study Description

Brief Summary

Following the degeneration of the macula and the loss of central vision, the patients naturally relocate the fixation point for high visual acuity peripherally, in an eccentric and healthy part of the retina (PRL), to compensate for visual impairments. However, in many cases, the PRL lands on a sub-optimal retinal area and becomes useless. Modern low-vision rehabilitation procedures for AMD patients include biofeedback training (BFT) to relocate the PRL to a healthy retinal patch and acquire better fixation skills. This study seeks to combine BFT with home-based immersive virtual-reality audiovisual stimulation and measure feasibility and potential effectiveness on oculomotor control and visual perception.

Condition or Disease Intervention/Treatment Phase
  • Device: Biofeedback Training
  • Device: Immersive Virtual-Reality
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
32 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Care Provider, Outcomes Assessor)
Primary Purpose:
Supportive Care
Official Title:
Visual Rehabilitation in Macular Degeneration: a Pilot Study on Biofeedback Training and Home-based Mobile Virtual-reality Stimulation
Actual Study Start Date :
Sep 15, 2021
Anticipated Primary Completion Date :
Aug 1, 2022
Anticipated Study Completion Date :
Feb 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Biofeedback Training

Biofeedback training (BFT): 1 sessions of 4 x 20 minutes blocks. Rest time of 5 minutes between blocks. 1 session per week for 4 weeks (4 sessions total). 30 min daily reading at home for 4 weeks.

Device: Biofeedback Training
Audiovisual stimulation

Experimental: Biofeedback Training + Immersive VR

Biofeedback training (BFT) [1 sessions of 4 x 20 minutes blocks. Rest time of 5 minutes between blocks], 1 session per week for 4 weeks (4 sessions total). 30 min daily reading at home for 4 weeks Immersive virtual-reality stimulation (IVR) [1 session of 3 blocks of 15 trials of 20 seconds each. Rest time is 1-2 minute(s) between blocks], 1 session every 2 days for 4 weeks (14 sessions total).

Device: Biofeedback Training
Audiovisual stimulation

Device: Immersive Virtual-Reality
Audiovisual stimulation

Outcome Measures

Primary Outcome Measures

  1. Feasibility of home-based IVR audiovisual stimulation [18 months]

    Feasibility objectives for our pilot study to be considered successful: Number of patients completing the stimulation protocol: ≥ 13 out of 16 patients (81%) per group. Number of IVR sessions performed by the patients to consider the stimulation protocol complete: ≥ 13 sessions out of 16 (81%). Number of consecutive virtual-reality induced symptoms and effects (VRISE) scores < 25: ≤ 3 per patient during the treatment period. Number of patient drop-outs due to cybersickness (discomfort symptoms experienced in VR): ≤ 3 (19%) during the treatment period. Number of randomized patients per week: ≥ 3 patients.

Secondary Outcome Measures

  1. Visual Acuity [from baseline to end of follow-up at 7 months]

    Change from baseline at 4 weeks, 1 month and 6 months: - Best Corrected Visual Acuity, distance and near vision (range 20/12.5 to <20/1000, higher score = better outcome)

  2. Retinal Sensitivity [from baseline to end of follow-up at 7 months]

    Change from baseline at 4 weeks,1 month and 6 months: - Mean retinal sensitivity (Macular Integrity Assessment, MAIA microperimetry - score: 0 dB to 36 dB, higher score = better outcome)

  3. Fixation stability [from baseline to end of follow-up at 7 months]

    Change from baseline at 4 weeks,1 month and 6 months: - Mean fixation stability (Macular Integrity Assessment, MAIA microperimetry - range 0.02 sq.deg. to 40.0 sq.deg., lowest score = better outcome)

  4. Contrast Sensitivity [from baseline to end of follow-up at 7 months]

    Change from baseline at 4 weeks, 1 month and 6 months: - Mean contrast sensitivity (Functional Acuity Contrast Test, FACT - range 0.48 cyc./deg. to 2.41 cyc./deg., higher score = better outcome)

  5. Reading Speed [from baseline to end of follow-up at 7 months]

    Change from baseline at 4 weeks,1 month and 6 months: - Mean reading speed (Minnesota Low Vision Reading test, MNREAD - range 0 word/minute to 280 word/minute, higher score = better outcome)

  6. Quality of Life Scores [from baseline to end of follow-up at 7 months]

    Change from baseline at 4 weeks,1 month and 6 months: - Quality of life scores (Veteran's Affairs Low Vision Questionnaire, VA-LVQ 48 - range -31.5 to +26.6, higher score = better outcome)

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Dry-AMD.

  • BCVA > 20/160.

  • Ability to follow the visual and auditory stimuli and training instructions.

  • Auditory test positive at 50Hz 25-60dBHL.

  • Home Wi-Fi access.

Exclusion Criteria:
  • Wet AMD.

  • Both eyes with media opacity that impairs microperimetry testing.

  • Inability to perform during testing and training.

  • Psychoactive drugs consumption.

  • 3 consecutive VRISE scores < 25 at inclusion.

  • History of vertigo or dizziness

  • Prior vision rehabilitation interventions.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Krembil Research Institute/Toronto Western Hospital Toronto Ontario Canada M5T 0S8

Sponsors and Collaborators

  • Michael Reber

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Michael Reber, Principal Investigator, University Health Network, Toronto
ClinicalTrials.gov Identifier:
NCT04685824
Other Study ID Numbers:
  • 2020410013068
First Posted:
Dec 28, 2020
Last Update Posted:
Sep 29, 2021
Last Verified:
Sep 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Michael Reber, Principal Investigator, University Health Network, Toronto
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 29, 2021